Sees FY23 revenue $200.5M, consensus $197.97M. “2023 was a landmark year for PacBio. The launch of the Revio system for scalable, accurate, long read sequencing and Onso, a short read sequencer with groundbreaking accuracy enabled PacBio to reach more customers than ever before and, in the process, achieve record financial results,” said Christian Henry, President and CEO of PacBio. “Our new platforms are enabling researchers to reimagine the study of genomics, increasing their ability to see more of, and deeper into, the genome. In 2024, I am excited to see how our customers leverage the power of our platforms, particularly as new large-scale genomics projects are initiated leveraging the power and economics of the Revio platform and as customers realize Onso’s extraordinary accuracy in a broad range of short-read applications.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PACB:
- PacBio initiated with neutral view at Guggenheim, here’s why
- PacBio initiated with bullish view at Stephens, here’s why
- PacBio initiated with neutral view at Wolfe Research, here’s why
- PacBio initiated with neutral view at Wolfe Research
- PacBio announces retirement of Botstein from board of directors